Show Summary Details
Page of

Stem cells and regenerative medicine 

Stem cells and regenerative medicine
Stem cells and regenerative medicine

Alexis J. Joannides

, Bhuvaneish T. Selvaraj

, and Siddharthan Chandran

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 February 2021

There is a great and unmet need for treatments that will deliver restorative solutions to patients with diseases hitherto considered irreparable. Advances in human pluripotent stem cell biology and gene-editing technology offer unprecedented opportunities for both drug discovery and translational therapies that will likely herald a new chapter of regenerative and personalized medicine. Consideration of three major target conditions for regenerative medicine—Parkinson’s disease, heart failure, and diabetes mellitus—emphasizes distinct and common challenges that must be overcome in order to realize the stem cell promise. Novel approaches to induce pluripotency from differentiated somatic cells and targeted genetic manipulation of stem cell populations, along with new insights derived from improved understanding of human pluripotent stem cell biology and increased recognition of endogenous stem cells, offers a range of mechanisms through which stem cells may be therapeutic.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.